Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01779570
Recruitment Status : Completed
First Posted : January 30, 2013
Last Update Posted : July 27, 2016
Information provided by (Responsible Party):
Nelson Lee, Chinese University of Hong Kong

Brief Summary:
Influenza lower respiratory tract infection (LRTI) is a major cause of morbidity and mortality worldwide. While viral replication can be suppressed by antiviral treatment, excessive inflammatory responses, which are increasingly recognized to contribute to severe influenza complications, remain unopposed. Macrolides have been used widely to treat community-acquired pneumonia, and shown to exert anti-inflammatory effects in other respiratory diseases, providing clinical benefits. In this randomized, open-label, multicenter study, we aim to investigate the anti-inflammatory effects of macrolide treatment in influenza LRTI. Its impacts on the cytokine response, viral clearance, symptoms and disease resolution will be studied. Such results may lead to the development of new therapeutic approaches against severe influenza infection, and provide better insights into disease pathogenesis.

Condition or disease Intervention/treatment Phase
Influenza Lower Respiratory Tract Infection Drug: Macrolide treatment Phase 4

Detailed Description:

Objectives: (1) We aim to investigate the anti-inflammatory effects of macrolide treatment in patients with influenza LRTI and the impact on viral clearance. (2) To investigate the impact of macrolide treatment on influenza symptom and disease resolution.

Design: A randomized, open-label, multicenter study.

Settings: Acute medical facilities in 3 general public hospitals in Hong Kong.

Subjects, Sampling and Intervention: Adult (>/=18 years) patients hospitalized for virologically confirmed influenza LRTI who fulfill the inclusion/exclusion criteria will be randomized to receive (1) azithromycin 500 mg p.o. for 5 days (in addition to antiviral, as part of usual care), or (2) no azithromycin (ie, antiviral alone, part of usual care) after informed consent. Serial blood samples will be collected for cytokine/inflammatory response assays. Serial nasopharyngeal swabs will be collected to assess for viral clearance. Symptoms, clinical progress, radiography and adverse events will be monitored.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections
Study Start Date : February 2013
Actual Primary Completion Date : April 2016
Actual Study Completion Date : April 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Macrolide treatment
Azithromycin 500 mg daily for 5 days
Drug: Macrolide treatment
No Intervention: No macrolide treatment
No azithromycin

Primary Outcome Measures :
  1. cytokine and inflammatory responses [ Time Frame: within 10 days post-intervention ]
    Serial measurements of selected cytokines/chemokines (e.g. interleukin-6, CXCL8) and proinflammatory molecules (e.g. DAMPs)

Secondary Outcome Measures :
  1. viral clearance [ Time Frame: within 10 days post-intervention ]
    Viral RNA and culture negativity in serially collected respiratory tract specimens

Other Outcome Measures:
  1. time to recovery [ Time Frame: within 10 days post-intervention ]
    e.g. time to symptom resolution, time to hospital discharge, etc

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. established influenza A or B infection by virologic tests
  2. age >/=18 years
  3. present within 4 days from illness onset
  4. clinical evidence of LRTI and require hospital care
  5. require antiviral (oseltamivir) treatment
  6. able to provide written, informed consent.

Exclusion Criteria:

  1. patients on immunosuppressants
  2. pregnant or lactating woman
  3. known hepatic failure, end-stage renal failure, cardiac arrhythmia (e.g. prolonged corrected QT interval >450 msec)
  4. known contraindications to azithromycin (e.g. allergic reaction)
  5. lack of consent for study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01779570

Hong Kong
Prince of Wales Hospital
Hong Kong, Hong Kong
Princess Margaret Hospital
Hong Kong, Hong Kong
Sponsors and Collaborators
Chinese University of Hong Kong
Principal Investigator: Nelson LS Lee, MD Chinese University of Hong Kong

Additional Information:

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Nelson Lee, Professor, Chinese University of Hong Kong Identifier: NCT01779570     History of Changes
Other Study ID Numbers: RGC CUHK468112
First Posted: January 30, 2013    Key Record Dates
Last Update Posted: July 27, 2016
Last Verified: July 2016

Keywords provided by Nelson Lee, Chinese University of Hong Kong:

Additional relevant MeSH terms:
Communicable Diseases
Influenza, Human
Respiratory Tract Infections
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Diseases
Anti-Inflammatory Agents